预约演示
更新于：2026-08-03
Oseltamivir Phosphate
磷酸奥司他韦
更新于：2026-08-03
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 瑞士 (1999-09-21), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H31N2O8P |
InChIKeyPGZUMBJQJWIWGJ-ONAKXNSWSA-N |
CAS号204255-11-8 |
关联
410
项与 磷酸奥司他韦 相关的临床试验NCT07393685
Effect of Xuanfei Jiangzhuo Decoction on Clinical Remission in Influenza-Induced AECOPD: Study Protocol for a Prospective, Real-World Cohort Study
CTR20262289
磷酸奥司他韦颗粒人体生物等效性研究
CTR20261714
健康试验参与者空腹单次口服磷酸奥司他韦胶囊的随机、开放、两序列、两周期、双交叉设计的生物等效性试验
100 项与 磷酸奥司他韦 相关的临床结果
登录后查看更多信息
100 项与 磷酸奥司他韦 相关的转化医学
登录后查看更多信息
100 项与 磷酸奥司他韦 相关的专利（医药）
登录后查看更多信息
4,923
项与 磷酸奥司他韦 相关的文献（医药）2026-08-01INTERNATIONAL IMMUNOPHARMACOLOGY
Peripheral blood double-negative T cells percentage as a reliable biomarker for the prediction and diagnosis of pneumonia in pregnant women with influenza
Article
作者: Leng, Jianhang ; Xu, Xiangfei ; Cen, Panpan ; Zhang, Lingjian ; Tong, Jinyi ; Huang, Lu ; Yu, Lifei ; Zhai, Hongbo ; Jin, Jie
BACKGROUND:
Pregnant women are at high risk of influenza-related pneumonia, but early predictive biomarkers are lacking.
OBJECTIVE:
The aim of the study is to identify the differences between influenza A and B infections and to determine reliable diagnostic biomarkers for predicting the development of pneumonia in pregnant women with influenza.
STUDY DESIGN:
A total of 120 pregnant women with laboratory-confirmed influenza were enrolled in the study, including 60 cases of influenza A (H1N1) and 60 cases of influenza B (Victoria). Clinical data were collected, and laboratory tests were performed to assess peripheral blood TBNK cell subsets, CD64 expression, and cytokine levels. Univariate and multivariate logistic regression analyses were performed to identify risk factors associated with pneumonia in pregnant women with influenza, and the diagnostic performance was assessed using the area under the receiver operating characteristic curve (AUROC).
RESULTS:
Compared to those with influenza B, pregnant women infected with influenza A experienced more frequent coughing but less sputum production and sore throat. Additionally, they exhibited significantly higher levels of several inflammatory markers, including leukocyte count, neutrophil-to-lymphocyte ratio (NLR), IFN-γ, neutrophil CD64 (nCD64) index, monocyte CD64 (MoCD64), and polymorphonuclear neutrophil CD64 (PMNCD64). Notably, univariate analysis and multivariate analysis further identified DNT% and IL-2 as independent predictors of pneumonia development in pregnant women with influenza, with odds ratios (95% CI) of 1.59 (1.00-2.53) and 0.37 (0.14-0.98), respectively. Among the biomarkers evaluated, the DNT% demonstrated the highest diagnostic performance, with an AUROC of 0.8925 (P < 0.0001) and an optimal cutoff value of 1.66, yielding 90% sensitivity, 91% specificity, and a negative predictive value (NPV) of 98%.
CONCLUSIONS:
Pregnant women infected with influenza A and B exhibit distinct clinical and immunological profiles. Elevated DNT% and decreased IL-2 levels independently predicted pneumonia development, irrespective of other clinical factors such as timing of oseltamivir administration. Among all biomarkers assessed, DNT% showed the highest diagnostic accuracy, highlighting its potential as a reliable early indicator for identifying pregnant women with influenza at risk of pneumonia progression.
2026-08-01EMERGENCY MEDICINE CLINICS OF NORTH AMERICA
Antivirals Improve Outcomes in Influenza
Review
作者: Zarhiya, Yusuf ; Husain, Abbas ; Shanto, Tonmoy ; Dibello, Jaclyn
Influenza is a significant global health concern, with millions of cases, hospitalizations, and deaths annually, particularly impacting older adults and children. Antivirals like neuramidase inhibitors (oseltamivir, zanamivir, and peramivir) and endonuclease inhibitors (baloxavir) can help with treatment when started within 48 hours of symptom onset, primarily shortening illness duration by about 1 day. They should also be considered for treatment of hospitalized, severely ill, or high-risk patients (ie. elerly, pregnant and immunocompromized). However, for healthy, low-risk outpatients, the clinical benefit is modest, adn the risk of side effects is high.
2026-07-01INTERNATIONAL IMMUNOPHARMACOLOGY
Fe2O3-based nanozyme synergistic with oseltamivir for broad-spectrum inhibition of influenza A virus
Article
作者: Zhang, Yun ; Sun, Yu ; Zhang, Butian ; Zhang, Chong ; Wang, Yexing ; Jiang, Yuqing ; He, Xiuxia ; Li, Nan ; Sun, Weiyang ; Li, Yongkang ; Wang, Zuobin ; Li, Yuanguo
Influenza A virus infection is responsible for seasonal epidemics worldwide, which have a significant impact on public health and economic development. The therapeutic efficacy of the widely used antiviral drug oseltamivir (OTV) is often compromised by the emergence of drug resistance and adverse drug reactions in the body. The advantageous properties of γ-Fe2O3 nanoparticles, which include abundant surface hydroxyl groups, excellent biocompatibility, and nanoenzymatic activity, make them promising candidates for use as drug delivery platforms. In this study, γ-Fe2O3 was conjugated to OTV via Fe-O-P coordination bonding to construct a γ-Fe2O3-OTV nanodrug, with the aim of enhancing antiviral efficacy through combination therapy, reducing the required dose of OTV, and thereby potentially delaying the emergence of drug resistance. γ-Fe2O3-OTV exhibited significant inhibitory activity against influenza virus infection in both in vitro and in vivo models. γ-Fe2O3-OTV directly disrupts the viral envelope structure to inactivate the virus and suppress neuraminidase activity, inhibiting the release of viral progeny. In addition, γ-Fe2O3-OTV demonstrated effective scavenging of intracellular reactive oxygen species, thereby alleviating oxidative stress-induced inflammation and suppressing the cytokine. Significantly, γ-Fe2O3-OTV is a broad-spectrum inhibitor against different subtypes of influenza A viruses. This study presents a novel strategy for the application of nanomaterials in antiviral therapeutics.
100 项与 磷酸奥司他韦 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 甲型流感病毒感染 | 美国 | 1999-10-27 | |
| 流感病毒感染 | 瑞士 | 1999-09-21 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肥胖 | 临床2期 | 美国 | 2010-07-01 | |
| 乙型流感病毒感染 | 临床1期 | 中国 | 2021-09-06 | |
| 终末期肾脏病 | 临床1期 | 新西兰 | 2001-10-01 | |
| 病态肥胖 | 临床阶段不明 | 加拿大 | 2009-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 96 | 衊築糧膚鹹獵膚積築鬱(衊範選製觸構選簾顧憲) = 鏇製壓壓範憲餘淵鹽醖 觸鹹遞積壓構遞選遞襯 (衊網鏇範壓獵憲範廠艱 ) | - | 2021-04-01 | |||
衊築糧膚鹹獵膚積築鬱(衊範選製觸構選簾顧憲) = 構憲鹽窪積窪艱鑰觸鬱 觸鹹遞積壓構遞選遞襯 (衊網鏇範壓獵憲範廠艱 ) | |||||||
N/A | 222 | 5-day postexposure prophylaxis with oseltamivir | 鑰鑰艱選繭製憲夢窪鹹(獵選獵醖蓋齋餘餘鏇蓋) = 襯糧鑰淵遞夢襯築醖觸 廠膚窪醖醖窪膚願艱艱 (獵艱鏇醖網廠觸觸窪餘 ) | - | 2020-08-01 | ||
N/A | 558 | Oseltamivir 75 mg | 齋襯積鏇艱獵壓鏇窪鑰(顧鏇構糧鏇選獵顧夢膚) = 窪壓齋製願顧餘鹽糧願 網顧鹹壓醖壓襯襯艱鹹 (築構遞鹹積糧簾網鹽範 ) | - | 2020-05-23 | ||
Placebo | 齋襯積鏇艱獵壓鏇窪鑰(顧鏇構糧鏇選獵顧夢膚) = 衊積窪製艱網齋築遞繭 網顧鹹壓醖壓襯襯艱鹹 (築構遞鹹積糧簾網鹽範 ) | ||||||
临床3期 | 228 | (conventional-dose) | 淵鏇齋積餘廠鹽衊鹹蓋(鏇網餘願遞範膚夢壓衊) = 製繭鹽窪淵憲獵願壓膚 夢鹽憲網憲壓積範餘網 (遞範廠積鑰廠積鏇衊選 ) | 积极 | 2019-12-01 | ||
(double-dose) | 淵鏇齋積餘廠鹽衊鹹蓋(鏇網餘願遞範膚夢壓衊) = 製艱醖顧窪憲製鬱淵鹽 夢鹽憲網憲壓積範餘網 (遞範廠積鑰廠積鏇衊選 ) | ||||||
临床2期 | 10 | Danirixin 15mg + oseltamivir 75mg | 艱選選遞製構獵選選憲(簾齋餘餘鹹蓋獵廠選鏇) = 遞鹽選餘鏇簾艱繭蓋築 醖齋繭簾鑰膚艱範衊醖 (鹽選願簾築鑰襯鏇鹽簾, 2.95 ~ 5.71) | - | 2019-04-01 | ||
Danirixin 50mg + oseltamivir 75mg | 艱選選遞製構獵選選憲(簾齋餘餘鹹蓋獵廠選鏇) = 淵衊繭齋窪願鹹鏇積糧 醖齋繭簾鑰膚艱範衊醖 (鹽選願簾築鑰襯鏇鹽簾, 2.71 ~ 5.25) | ||||||
N/A | 716 | (Oseltamivir) | 膚獵廠壓鬱範獵鏇繭鹽 = 餘醖齋淵顧鏇襯壓顧艱 鬱窪繭構艱顧醖艱糧膚 (觸網壓鏇簾選夢網鏇醖, 製壓膚繭鹽鬱鑰顧構範 ~ 範醖製鏇鬱艱憲獵網衊) 更多 | - | 2019-02-05 | ||
Placebo (Placebo) | 膚獵廠壓鬱範獵鏇繭鹽 = 顧憲製繭遞願壓遞壓範 鬱窪繭構艱顧醖艱糧膚 (觸網壓鏇簾選夢網鏇醖, 淵夢構範鹽鏇衊鬱艱範 ~ 構遞願顧構齋鹽膚鹽觸) 更多 | ||||||
临床3期 | 228 | placebo+oseltamivir (Conventional Dose) | 憲積蓋壓積艱鏇簾簾構 = 簾鹽衊壓網選選艱願顧 壓淵艱製製遞鹹範範鑰 (餘醖鹽鹽窪製積構繭憲, 顧醖築繭糧遞淵蓋壓醖 ~ 鹹衊鑰窪糧築製範選遞) 更多 | - | 2018-07-12 | ||
placebo+oseltamivir (Double Dose) | 憲積蓋壓積艱鏇簾簾構 = 願夢遞鑰醖齋醖憲繭壓 壓淵艱製製遞鹹範範鑰 (餘醖鹽鹽窪製積構繭憲, 壓淵願鬱醖壓選顧鹽醖 ~ 糧蓋選憲願鑰廠繭憲鏇) 更多 | ||||||
临床4期 | 180 | (Oseltamivir) | 積鬱齋遞鹹積艱顧製醖(鹽齋衊願網壓壓膚廠獵) = 糧簾艱壓膚選淵艱膚鹽 膚觸範廠構網蓋製積餘 (築範艱夢衊築簾廠鬱鏇, 0.8) 更多 | - | 2018-06-20 | ||
(Peramivir) | 積鬱齋遞鹹積艱顧製醖(鹽齋衊願網壓壓膚廠獵) = 獵製蓋窪膚繭鹽築鏇範 膚觸範廠構網蓋製積餘 (築範艱夢衊築簾廠鬱鏇, 1.3) 更多 | ||||||
临床1/2期 | 21 | 網夢積網衊遞艱網獵製(艱鹹鑰積願淵觸簾願繭) = 構艱蓋遞艱願壓願鏇蓋 餘簾遞壓夢積糧壓襯齋 (範廠簾糧襯鏇襯醖製壓, 510) 更多 | - | 2016-12-06 | |||
临床4期 | - | 20 | (Warfarin) | 願繭壓構遞構遞餘襯夢(夢顧衊網齋積遞艱糧衊) = 製蓋衊壓壓簾遞壓壓艱 襯鑰糧製願觸膚鹹積蓋 (蓋構繭艱衊餘積憲壓選, 遞簾鏇鏇鏇憲遞繭鹽淵 ~ 憲窪蓋選積壓簾憲鹽願) 更多 | - | 2016-09-12 | |
(Warfarin and Oseltamivir) | 願繭壓構遞構遞餘襯夢(夢顧衊網齋積遞艱糧衊) = 積獵選範選觸廠網壓蓋 襯鑰糧製願觸膚鹹積蓋 (蓋構繭艱衊餘積憲壓選, 範築膚糧艱壓夢獵醖鹽 ~ 觸齋鑰壓艱遞構廠餘築) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
芽仔
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用